FRINK Linked Data Fragments server

Matches in SemOpenAlex for { <https://semopenalex.org/work/W2906929734> ?p ?o ?g. }

• W2906929734 endingPage "4059" @default.
• W2906929734 startingPage "4059" @default.
• W2906929734 abstract "Abstract Introduction: Treatment of acute myeloid leukemia (AML) has remained largely unchanged for several decades despite the emergence of new agents. Long-term survival for patients aged >60 years is less than 10% (median survival 10.5 months). Targeting the proteasome in treating AML is attractive, since leukemia stem cells have demonstrated sensitivity to proteasome inhibition, perhaps through down regulation of nuclear NF-KB (Guzman, Blood 2001). Preclinical studies in leukemia cell lines revealed synergistic cytotoxicity when bortezomib, a proteasome inhibitor, was combined with the standard agents daunorubicin and cytarabine. We have shown that adding bortezomib to standard treatment in AML results in a high remission rate, although neurotoxicity was noted among treated patients, 12% grade 3 sensory (Attar, …, Amrein, et al. Clin Cancer Res 2008, Attar, … Amrein, J Clin Oncol 2012). The next generation proteasome inhibitor, ixazomib, which is less frequently associated with neurotoxicity, was therefore selected for combination with conventional chemotherapy in this phase I trial. The primary objective was to determine the maximum tolerated dose (MTD) in the combination, initially in induction, and then in combination with consolidation in a subsequent portion of the overall study. We report here the results of the induction portion of the study, which has been completed. Methods: Adults >60 years of age with newly diagnosed AML were screened for eligibility. Patients with secondary AML were eligible, including those with prior hypomethylating agent therapy for myelodysplastic syndromes (MDS). We excluded those with promyelocytic leukemia. The induction treatment consisted of the following: cytarabine 100 mg/m2/day by continuous IV infusion, Days 1-7; daunorubicin 60 mg/m2/day IV, Days 1, 2, 3; ixazomib orally at the cohort dose, Days 2, 5, 9, and 12 A standard 3 + 3 patient cohort dose escalation design was used to determine whether the dose of ixazomib could be safely escalated in 3 cohorts (1.5 mg/day, 2.3 mg/day, 3.0 mg/day), initially in induction and subsequently in consolidation. The dose of 3.0 mg/day was the maximum planned for this study. The determined MTD of ixazomib in the first portion of the trial would be used during induction in the second portion, which seeks to test dose escalation of ixazomib during consolidation. Secondary objectives included rate of complete remission and disease-free survival. Results: Fourteen patients have been analyzed for toxicity and activity during the induction portion of the study. There were 4 (28%) patients with either secondary AML or treatment related AML, 9 (64%) were male, and the median age was 67 years (range 62-80 years). There have been no grade 5 toxicities due to study drug. Three patients died early due to leukemia, 2 of which were replaced for assessment of the MTD. Nearly all the grade 3 and 4 toxicities were hematologic (Table). There was 1 DLT (grade 3 thrombocytopenia) indicated at the highest dose level. There has been no neurotoxicity with ixazomib to date. Among the 14 patients, there have been 10 complete remissions (CR's) and 1 CRi for a remission rate of 79%. Conclusions: The highest dose level planned for this portion of the trial, 3.0 mg of ixazomib, was reached with 1 DLT and is the recommended dose for induction in the next portion of this study, which will seek to determine a safe ixazomib dose in combination with conventional consolidation therapy. That no neurotoxicity was encountered was reassuring, and the remission rate in this older adult population is favorable. Table. Table. Disclosures Amrein: Takeda: Research Funding. Attar:Agios: Employment, Equity Ownership. Brunner:Takeda: Research Funding; Novartis: Research Funding; Celgene: Consultancy, Research Funding. Fathi:Celgene: Consultancy, Honoraria, Research Funding; Boston Biomedical: Consultancy, Honoraria; Astellas: Honoraria; Agios: Honoraria, Research Funding; Jazz: Honoraria; Seattle Genetics: Consultancy, Honoraria; Takeda: Consultancy, Honoraria." @default.
• W2906929734 created "2019-01-11" @default.
• W2906929734 creator A5003947352 @default.
• W2906929734 creator A5009091754 @default.
• W2906929734 creator A5009387581 @default.
• W2906929734 creator A5010057352 @default.
• W2906929734 creator A5011957744 @default.
• W2906929734 creator A5028014379 @default.
• W2906929734 creator A5030996883 @default.
• W2906929734 creator A5031787192 @default.
• W2906929734 creator A5034391908 @default.
• W2906929734 creator A5037613767 @default.
• W2906929734 creator A5051338623 @default.
• W2906929734 creator A5057041174 @default.
• W2906929734 creator A5058921568 @default.
• W2906929734 creator A5063699585 @default.
• W2906929734 creator A5065595440 @default.
• W2906929734 creator A5071293141 @default.
• W2906929734 creator A5072536261 @default.
• W2906929734 creator A5081051762 @default.
• W2906929734 creator A5081484812 @default.
• W2906929734 creator A5089205998 @default.
• W2906929734 creator A5089274301 @default.
• W2906929734 date "2018-11-29" @default.
• W2906929734 modified "2023-10-16" @default.
• W2906929734 title "Phase I Study of Ixazomib in Addition to Chemotherapy for the Treatment of Acute Myeloid Leukemia in Older Adults" @default.
• W2906929734 doi "https://doi.org/10.1182/blood-2018-99-117566" @default.
• W2906929734 hasPublicationYear "2018" @default.
• W2906929734 type Work @default.
• W2906929734 sameAs 2906929734 @default.
• W2906929734 citedByCount "0" @default.
• W2906929734 crossrefType "journal-article" @default.
• W2906929734 hasAuthorship W2906929734A5003947352 @default.
• W2906929734 hasAuthorship W2906929734A5009091754 @default.
• W2906929734 hasAuthorship W2906929734A5009387581 @default.
• W2906929734 hasAuthorship W2906929734A5010057352 @default.
• W2906929734 hasAuthorship W2906929734A5011957744 @default.
• W2906929734 hasAuthorship W2906929734A5028014379 @default.
• W2906929734 hasAuthorship W2906929734A5030996883 @default.
• W2906929734 hasAuthorship W2906929734A5031787192 @default.
• W2906929734 hasAuthorship W2906929734A5034391908 @default.
• W2906929734 hasAuthorship W2906929734A5037613767 @default.
• W2906929734 hasAuthorship W2906929734A5051338623 @default.
• W2906929734 hasAuthorship W2906929734A5057041174 @default.
• W2906929734 hasAuthorship W2906929734A5058921568 @default.
• W2906929734 hasAuthorship W2906929734A5063699585 @default.
• W2906929734 hasAuthorship W2906929734A5065595440 @default.
• W2906929734 hasAuthorship W2906929734A5071293141 @default.
• W2906929734 hasAuthorship W2906929734A5072536261 @default.
• W2906929734 hasAuthorship W2906929734A5081051762 @default.
• W2906929734 hasAuthorship W2906929734A5081484812 @default.
• W2906929734 hasAuthorship W2906929734A5089205998 @default.
• W2906929734 hasAuthorship W2906929734A5089274301 @default.
• W2906929734 hasConcept C104317684 @default.
• W2906929734 hasConcept C126322002 @default.
• W2906929734 hasConcept C143998085 @default.
• W2906929734 hasConcept C2776364478 @default.
• W2906929734 hasConcept C2776601000 @default.
• W2906929734 hasConcept C2776611710 @default.
• W2906929734 hasConcept C2776694085 @default.
• W2906929734 hasConcept C2777478702 @default.
• W2906929734 hasConcept C2778041864 @default.
• W2906929734 hasConcept C2778367456 @default.
• W2906929734 hasConcept C2778461978 @default.
• W2906929734 hasConcept C2778729363 @default.
• W2906929734 hasConcept C2781021840 @default.
• W2906929734 hasConcept C2781121885 @default.
• W2906929734 hasConcept C55493867 @default.
• W2906929734 hasConcept C71924100 @default.
• W2906929734 hasConcept C86803240 @default.
• W2906929734 hasConceptScore W2906929734C104317684 @default.
• W2906929734 hasConceptScore W2906929734C126322002 @default.
• W2906929734 hasConceptScore W2906929734C143998085 @default.
• W2906929734 hasConceptScore W2906929734C2776364478 @default.
• W2906929734 hasConceptScore W2906929734C2776601000 @default.
• W2906929734 hasConceptScore W2906929734C2776611710 @default.
• W2906929734 hasConceptScore W2906929734C2776694085 @default.
• W2906929734 hasConceptScore W2906929734C2777478702 @default.
• W2906929734 hasConceptScore W2906929734C2778041864 @default.
• W2906929734 hasConceptScore W2906929734C2778367456 @default.
• W2906929734 hasConceptScore W2906929734C2778461978 @default.
• W2906929734 hasConceptScore W2906929734C2778729363 @default.
• W2906929734 hasConceptScore W2906929734C2781021840 @default.
• W2906929734 hasConceptScore W2906929734C2781121885 @default.
• W2906929734 hasConceptScore W2906929734C55493867 @default.
• W2906929734 hasConceptScore W2906929734C71924100 @default.
• W2906929734 hasConceptScore W2906929734C86803240 @default.
• W2906929734 hasIssue "Supplement 1" @default.
• W2906929734 hasLocation W29069297341 @default.
• W2906929734 hasOpenAccess W2906929734 @default.
• W2906929734 hasPrimaryLocation W29069297341 @default.
• W2906929734 hasRelatedWork W1978664359 @default.
• W2906929734 hasRelatedWork W2151934335 @default.
• W2906929734 hasRelatedWork W2271311441 @default.
• W2906929734 hasRelatedWork W2405192714 @default.
• W2906929734 hasRelatedWork W2589187468 @default.
• W2906929734 hasRelatedWork W2891757930 @default.
• W2906929734 hasRelatedWork W2906929734 @default.

• next